ESSA Pharma

ESSA Pharma receives $4M from Research Institute of Texas

Wednesday, February 1, 2017

ESSA Pharma, a pharmaceutical company, currently in the clinical development stage, focused on the development of small molecule drugs for the treatment of prostate cancer, announced the receipt of a $4 million payment from the Cancer Prevention Research Institute of Texas (CPRIT). The payment is part of a total non-dilutive grant of $12 million, repayable out of potential product revenues, which was originally awarded in February 29, 2014.

[Read More]